Peptides for Therapy and Diagnosis of Alzheimer's Disease

Author(s): Susanne Aileen Funke, Dieter Willbold

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 6 , 2012

Become EABM
Become Reviewer


Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post mortem, whereas the diagnosis “probable AD” can be established earliest when severe clinical symptoms appear. Specific neuropathological changes like neurofibrillary tangles and amyloid plaques define AD. Amyloid plaques are mainly composed of the amyloid-βpeptide (Aβ). Several lines of evidence suggest that the progressive concentration and subsequent aggregation and accumulation of Aβplay a fundamental role in the disease progress. Therefore, substances which bind to Aβ and influence aggregation thereof are of great interest. An enormous number of organic substances for therapeutic purposes are described. This review focuses on peptides developed for diagnosis and therapy of AD and discusses the pre- and disadvantages of peptide drugs.

Keywords: Alzheimer's disease, , amyloid-β, therapy, peptides, diagnosis, neurodegenerative, symptomatic, dementia, protofibrils, diffusible ligands

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [755 - 767]
Pages: 13
DOI: 10.2174/138161212799277752

Article Metrics

PDF: 75